At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downwards re-rating after the company started 2024 on a soft note. A setback in its pipeline, a softer ...
MarketBeat on MSN1d
Gilead's Stock Surge: What's Fueling the Momentum?Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...
Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...
TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...
An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
(Reuters) - Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback